Cargando…

Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption

Background: The umbrella term ATMPs (Advanced Therapy Medicinal Products) comprises cell therapies, gene therapeutics and tissue engineered products. After implementation of the Regulation 1394/2007, only a couple of products have obtained a centralized European marketing authorisation. Objectives:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eder, Claudia, Wild, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493298/ https://www.ncbi.nlm.nih.gov/pubmed/31069029 http://dx.doi.org/10.1080/20016689.2019.1600939

Ejemplares similares

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
por: Duranti, Simona, et al.
Publicado: (2021)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
por: Trias, Esteve, et al.
Publicado: (2022)

Forecasted Size of Measles Outbreaks Associated With Vaccination Exemptions for Schoolchildren
por: Sinclair, David R., et al.
Publicado: (2019)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
por: Jorda, Anselm, et al.
Publicado: (2020)

Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
por: Grössmann, Nicole, et al.
Publicado: (2017)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

The Exempts
Publicado: (1891)

EU research infrastructure offered VAT exemption
Publicado: (2009)

Tax Exemption
Publicado: (1955)

Tax Exemption
Publicado: (1955)

Tax Exemption
Publicado: (1955)

Tax Exemption
Publicado: (1955)

Tax Exemption
Publicado: (1956)

Tax Exemption
Publicado: (1955)

No Profession Exempt
por: Towner, Ausburn
Publicado: (1879)

The Decline of Deep Brain Stimulation for Obsessive–Compulsive Disorder Following FDA Humanitarian Device Exemption Approval
por: Pinckard-Dover, Heather, et al.
Publicado: (2021)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

The GDPR and the research exemption: considerations on the necessary safeguards for research biobanks
por: Staunton, Ciara, et al.
Publicado: (2019)

Exemptions and Limited Institutional Review Board Review: A Practical Look at the 2018 Common Rule Requirements for Exempt Research
por: Walch-Patterson, Amelia
Publicado: (2020)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?
por: Maiese, Aniello, et al.
Publicado: (2022)

Benefits for Exempt Persons
Publicado: (1914)

Parental attitudes and perceptions associated with childhood vaccine exemptions in high-exemption schools
por: Pottinger, Heidi L., et al.
Publicado: (2018)

EMA : escala multidimensional de asertividad : manual /
por: Flores Galaz, Mirta Margarita
Publicado: (2004)

Ema, la cautiva
por: Aira, César, 1949-

Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)
por: Sánchez-Guijo, Fermín, et al.
Publicado: (2023)

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
por: Zeitoun, Jean-David, et al.
Publicado: (2017)

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
por: Solassol, Isabelle, et al.
Publicado: (2019)

Comparing the Value of Nonprofit Hospitals’ Tax Exemption to Their Community Benefits
por: Herring, Bradley, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5oj977bjik6f1uos4fea7mimi7